Get the Stockscreener App
1.91
8.52%
0.15
Sellas Life Sciences Group Inc stock is traded at $1.91, with a volume of 2.14M.
It is up +8.52% in the last 24 hours and up +3.80% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$1.76
Open:
$1.78
24h Volume:
2.14M
Relative Volume:
0.77
Market Cap:
$201.12M
Revenue:
-
Net Income/Loss:
$-37.34M
P/E Ratio:
-1.4044
EPS:
-1.36
Net Cash Flow:
$-36.91M
1W Performance:
+17.18%
1M Performance:
+3.80%
6M Performance:
+50.39%
1Y Performance:
+45.80%
1-Day Range:
$1.757
$1.92
1-Week Range:
$1.61
$1.92
52-Week Range:
$0.772
$2.2691
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.91 | 182.16M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
SELLAS Life Sciences’ Triumphant Advances - StocksToTrade
Sellas Life Sciences: SLS009’s Phase 2 Sets Up A Promising 2026 (NASDAQ:SLS) - Seeking Alpha
SELLAS Life Sciences Rises On Cancer Trial Progress And New Listings - Finimize
What’s the fair value of SELLAS Life Sciences Group Inc. stockEarnings Recap Summary & Low Drawdown Momentum Ideas - mustnews.co.kr
Published on: 2025-08-15 06:21:10 - beatles.ru
Chart Patterns Forming a Bullish Setup in SELLAS Life Sciences Group Inc.2025 Technical Patterns & Real-Time Volume Trigger Notifications - beatles.ru
Optimistic Buy Rating for SELLAS Life Sciences Group Driven by Promising Trial Results and Financial Stability - TipRanks
Sellas Life Sciences Reports Q2 2025 Financial Results - TipRanks
Sellas Life Sciences Group Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Sellas Life Sciences' GPS Trial Continues with Positive IDMC Recommendation - AInvest
SELLAS Life Sciences Receives Positive IDMC Recommendation to Continue Phase 3 REGAL Trial of GPS in AML. - AInvest
Sellas Life Sciences Group Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 Regal Trial of GPS in AML Without Modification - MarketScreener
SELLAS Life Sciences Gets Positive IDMC Nod To Continue Phase 3 Trial Of AML Treatment - Nasdaq
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification - The Manila Times
IDMC recommends continuation of Phase 3 AML trial for galinpepimut-S - Investing.com India
SELLAS Life Sciences Announces Independent Data Monitoring - GlobeNewswire
SELLAS Phase 3 Cancer Drug GPS Clears Critical Safety Review, Final Data Expected This Year - Stock Titan
SELLAS Life Sciences Group Inc. Consolidation Zone May Signal AccumulationMulti-Bagger Potential Stock Forecast Tools Released - metal.it
What institutional investors are buying SELLAS Life Sciences Group Inc. stockGet alerts on top growth stocks daily - Jammu Links News
What analysts say about SELLAS Life Sciences Group Inc. stockDiscover investment plans that deliver results - Jammu Links News
What is the risk reward ratio of investing in SELLAS Life Sciences Group Inc. stockBuild a portfolio for long-term financial success - Jammu Links News
Does SELLAS Life Sciences Group Inc. stock perform well during market downturnsExceptional profit velocity - Jammu Links News
How does SELLAS Life Sciences Group Inc. compare to its industry peersBreakout stock performance - Jammu Links News
What are the latest earnings results for SELLAS Life Sciences Group Inc.Achieve fast wealth growth with smart picks - Jammu Links News
What are analysts’ price targets for SELLAS Life Sciences Group Inc. in the next 12 monthsRapid profit acceleration - Jammu Links News
What makes SELLAS Life Sciences Group Inc. stock price move sharplyGet professional advice for portfolio optimization - Jammu Links News
What are SELLAS Life Sciences Group Inc. company’s key revenue driversInvest smarter with daily stock recommendations - Jammu Links News
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised) - MSN
What is the dividend policy of SELLAS Life Sciences Group Inc. stockRetirement Planning Watchlist For Every Investor - Jammu Links News
SELLAS Life Sciences : Corporate PresentationAugust 2025 - MarketScreener
What catalysts could drive SELLAS Life Sciences Group Inc. stock higher in 2025Wealth Building Trend Scanner For Smart Trading - Jammu Links News
Published on: 2025-07-31 14:02:06 - beatles.ru
Sector Leaders Rotate Capital Into SELLAS Life Sciences Group Inc.Stock Screener With Smart Filters Highlights Top Picks - beatles.ru
Published on: 2025-07-29 08:30:26 - metal.it
What risks could impact SELLAS Life Sciences Group Inc. stock performanceIntraday Trend Analysis for Fast Gains Released - beatles.ru
Should I hold or sell SELLAS Life Sciences Group Inc. stock in 2025Market Forecast Updates That Work - Jammu Links News
How strong is SELLAS Life Sciences Group Inc. company’s balance sheetFree Technical Analysis Support - jammulinksnews.com
How Resilient Is SELLAS Life Sciences Group Inc. Stock During Economic DownturnsTop Performer Shortlist - metal.it
SELLAS Life Sciences Group Inc. Stock Analysis and ForecastTriple-digit profit margins - PrintWeekIndia
What institutions are buying SELLAS Life Sciences Group Inc. stock nowStrong return on assets - Jammu Links News
What drives SELLAS Life Sciences Group Inc. stock priceUnprecedented growth rates - PrintWeekIndia
Is SELLAS Life Sciences Group Inc. a good long term investmentExceptional profit potential - PrintWeekIndia
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sellas Life Sciences Group Inc Stock (SLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wasman Jane | Director |
May 30 '25 |
Buy |
1.69 |
20,000 |
33,800 |
30,400 |
| Kalin Katherine Bach | Director |
May 22 '25 |
Buy |
1.80 |
20,000 |
36,000 |
41,000 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):